US9732075 — Benzimidazole-proline derivatives
Method of Use · Assigned to Idorsia Pharmaceuticals Ltd · Expires 2033-06-12 · 7y remaining
What this patent protects
This patent protects benzimidazole-proline derivatives, specifically compounds of formula (I), and their use as orexin receptor antagonists.
USPTO Abstract
The present invention relates to compounds of the formula (I) wherein Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b and (R 5 ) n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-620 |
— | daridorexant-hydrochloride |
U-620 |
— | daridorexant-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.